Nirmesh Patel

Cambridge Cancer Genomics

Nirmesh Patel is the Chief Scientific Officer of Cambridge Cancer Genomics, a smart genomics company using liquid biopsies to better guide cancer therapy choice and offer truly personalised medicine.

Trained as a biomedical scientist at King’s College London, he has 10 years of experience in oncology research and a PhD in Translational Cancer Medicine where he used data science and bioinformatics to identify novel targets in breast cancer and biomarkers to predict patient response, launching multiple drug discovery efforts in collaboration with pharma.

He has always sat at the interface between laboratory research, data science and the clinic and is unifying the three fields with a mission to improve cancer patient treatment.

dont miss

Monitoring cancer evolution through smart genomics and liquid biopsies

One of the major advantages of liquid biopsies is the ability to probe the same patient multiple times with low invasiveness. Thus, allowing us to monitor the evolution of the tumour and identify markers that indicate response and resistance to therapy. Here we show how the analysis of the chronological mutational landscape of tumours can offer new therapeutic approaches for limiting tumour recurrence.

EVEN MORE SEMINARS

  • Stéfan Halbherr: Speaking at the Oncology Convention

    Stéfan Halbherr
    InnoMedica

    Liposome pipeline addressing unmet medical needs in oncology, imaging, and neurodegeneration

  • Rob Duncombe: Speaking at the Oncology Convention

    Rob Duncombe
    The Christie NHS Foundation Trust

    Medicine Optimisation in Oncology. How to achieve best value.

  • Mr Naga Venkatesh Jayanthi MD, FRCS: Speaking at the Oncology Convention

    Mr Naga Venkatesh Jayanthi MD, FRCS
    Bupa - Consultant Surgeon

    Minimal Invasive Oesophagectomy – where are we going?

  • Glenn Flux: Speaking at the Oncology Convention

    Glenn Flux
    Royal Marsden Hospital

    The emergence and resurgence of radiotherapeutics for cancer treatment

  • Laura Allington: Speaking at the Oncology Convention

    Laura Allington
    University College London Hospitals NHS Foundation Trust

    Operational challenges of planning a new NHS high energy proton service.